Impact of high-throughput screening in biomedical research

  • Nat Rev Drug Discov. 2011 Mar;10(3):188-95. doi: 10.1038/nrd3368.
Ricardo Macarron  1 ,  Martyn N Banks ,  Dejan Bojanic ,  David J Burns ,  Dragan A Cirovic ,  Tina Garyantes ,  Darren V S Green ,  Robert P Hertzberg ,  William P Janzen ,  Jeff W Paslay ,  Ulrich Schopfer ,  G Sitta Sittampalam
Affiliations
  • 1. Department of Sample Management Technologies, GlaxoSmithKline, Mail Stop UP 12-200, 1250S Collegeville Rd, Collegeville, Pennsylvania 19426, USA. [email protected]
PMID: 21358738 DOI: 10.1038/nrd3368
Abstract

High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.